Senhwa Biosciences, Inc. engages in the research and development of anticancer drug and active pharmaceutical ingredient. It has two agents in clinical development for cancer, which includes CX-5461, a compound that activates p53 and kills cancer cells; and CX-4945, a compound that controls the growth and proliferation of cancer cells. The company was founded by Tai Sen Soong on November 16, 2012 and is headquartered in New Taipei, Taiwan.